Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease
Study Details
Study Description
Brief Summary
This study is a randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the efficacy and safety of GLH8NDE in patients with Dry Eye Disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: GLH8NDE 5% and GLH8NDE Placebo Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo |
Drug: 5% GLH8NDE
5% GLH8NDE as eye drops
Drug: Placebo
Placebo as eye drops
|
| Experimental: GLH8NDE 5% Total 6 times 1 drop of GLH8NDE 5% |
Drug: 5% GLH8NDE
5% GLH8NDE as eye drops
|
| Placebo Comparator: GLH8NDE Placebo Total 6 times 1 drop of GLH8NDE Placebo |
Drug: Placebo
Placebo as eye drops
|
Outcome Measures
Primary Outcome Measures
- The change of Total Corneal Staining Score (TCSS) [Between 1 day before first IP administration and 4 weeks]
To 4 weeks after baseline visit using NEI scale (total between 0 and 15 scores)
Secondary Outcome Measures
- The change of Total Corneal Staining Score (TCSS) [Between 1 day before first IP administration and 2, 8, 12 weeks]
To 2, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 15 scores, higher scores mean a worse outcome)
- The change of Inferior Corneal Staining Score (ICSS) [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 15 scores, higher scores mean a worse outcome)
- The change of Conjunctival Staining Score [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 18 scores, higher scores mean a worse outcome)
- The change of Tear Film Break-up time(TFBUT) [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit
- The change of Schirmer I test [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit
- The change of 5-item dry questionnaire (DEQ-5) [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit (total between 0 and 22 socres, higher scores mean a worse outcome)
- The change of Ehlers-Danlos Syndrome (EDS) by Visual Analogue Scale (VAS) [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit (total between 0 and 100 scores, highter scores mean a worse outcome)
- The change of Ccular Discomfort Score(ODS) [Between 1 day before first IP administration and 2, 4, 8, 12 weeks]
To 2, 4, 8, 12 weeks after baseline visit (total 0 and 4 scores, higher scores mean a worse outcome)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject who is the age of older than 19 years at the screeing visit
-
Subject who has symptom at least one or more as below for six months(Irritation, foreign body sensation, burning, mucus discharge, blurring, itching, photophobia, tired or heavy feeling and pain)
-
Subject with dry eye syndrome who meet all of the following criteria among the left and/or right eyes at the time of screening and baseline visit.
-
Over six grade as fluorescein corneal staining by National Eye Institute scale
-
Schirmer I test ≤ 10 mm/5 min.
-
TFBUT ≤ 6 seconds
-
At the screening and baseline visit, the intraocular pressure(IOP) of both eyes is more than 5 mmHg and below 22 mmHg
-
At the screening and baseline visit, biocular best corrected visual acuity(BCVA) are over 0.2(=+0.7 logMAR or Snellen 20/100)
-
At the baseline visit, over 80% administration compliance during run-in period as placebo in single blind
-
Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial
Exclusion Criteria:
-
Ophthalmic diseases that may confuse the interpretation of clinical trial results, such as clinically significant corneal surface disease, abnormal corneal sensitivity, and abnormal tearing
-
Subject with wounds caused by refractive surgery such as LASIK surgery (However, if it does not affect the clinical trial compliance and result evaluation according to the investigator's judgment, participation is possible.)
-
Subject with the following concomitant diseses at screening visit.
-
Eyelid disease (blepharopathy, blepharolysis, valgus, varus valgus, etc.), conjunctival relaxation, cataracts, and eye diseases requiring treatment
-
Sjogren's syndrome and secondary Sjogren's syndrome (rheumatoid arthritis, systemic lupus erythematosus, etc.)
-
Diabetes not controlled despite appropriate treatment (hemoglobin A1c (HbA1c)> 9%)
-
Subject with the following systemic diseases that are not controlled High blood pressure that is not controlled despite administration of antihypertensive drugs (systolic blood pressure (SBP)/diastolic blood pressure (DBP)>160/100 mmHg) Clinically significant cardiopulmonary disease despite appropriate treatment
-
Acute active hepatitis A, active hepatitis B or C
- Subject with the following medical history (including surgical history) at screening visit
-
Organ transplant or bone marrow transplant
-
History of known immunodeficiency disease or human immunodeficiency virus (HIV) infection
-
Ophthalmic surgery within 1 year before screening (including LASIK/LASEK surgery)
-
Subject who has undergone punctal occlusion and have not passed 12 weeks from the time point below.
After punctal cauterization using electrocautery. After inserting a permanent, semi-permanent punctal plug. If a temporary punctal plug is inserted, remove the punctal plug.
- Subject who has administered the following drugs before the clinical trial or who need to be administered during the clinical trial.
-
Cyclosporine eye drops within 6 weeks before screening
-
Ophthalmic solutions or antibiotics due to blepharitis, meibomian gland disease, herpes zoster, and eye infection within 6 weeks before screening
-
Drugs that cause dry eye within 6 weeks before screening (anticholinergics, isotretinoin, etc.)
-
Oral aspirin or drugs containing aspirin within 6 weeks before screening
-
Contains corticosteroids, mast cell stabilizers, antihistamines, anti-inflammatory drugs (NSAIDs, etc.), gamma linolenic acid, or omega-3 fatty acids within 6 weeks before screening
-
Other ophthalmic solutions within 3 days before screening
-
Subject who wears contact lenses within 1 week before screening or who needs to wear them during the clinical trial
-
Subject with alcoholism or drug abuse history within 1 year before screening
-
Pregnant women, lactating women, and those who disagree with appropriate contraception during the clinical trial (visit 1 to visit 6)
-
Subject with hypersensitivity to investigator's drugs or their excipients
-
Subject who participated in other clinical trials within 4 weeks before screening and received/received investigator's drug or clinical trial medical devices
-
Subject judged by other investigators to be inappropriate to participate in this clinical trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Samsung Medical Center | Seoul | Gangnam-gu | Korea, Republic of | 06351 |
Sponsors and Collaborators
- GL Pharm Tech Corporation
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GLH8NDE-201